Does the media refer more to BEAM or DNLI?

In the previous week, Beam Therapeutics had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 5 mentions for Beam Therapeutics and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.26 beat Beam Therapeutics' score of 0.96 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DNLI or RDY?

In the previous week, Dr. Reddy's Laboratories had 7 more articles in the media than Denali Therapeutics. MarketBeat recorded 9 mentions for Dr. Reddy's Laboratories and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.26 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ELAN or DNLI?

In the previous week, Elanco Animal Health had 13 more articles in the media than Denali Therapeutics. MarketBeat recorded 15 mentions for Elanco Animal Health and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.26 beat Elanco Animal Health's score of 1.18 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 9 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DNLI or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 6 more articles in the media than Denali Therapeutics. MarketBeat recorded 8 mentions for Arrowhead Pharmaceuticals and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.26 beat Arrowhead Pharmaceuticals' score of 1.05 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DNLI or ABVX more profitable?

Denali Therapeutics' return on equity of -52.20% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Denali Therapeutics N/A -52.20% -43.86% Abivax N/A -99.02% -70.26%

Does the media prefer DNLI or ABVX?

In the previous week, Abivax had 22 more articles in the media than Denali Therapeutics. MarketBeat recorded 24 mentions for Abivax and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.26 beat Abivax's score of 0.18 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 3 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 4 Very Negative mention(s) Neutral

Denali Therapeutics (DNLI) Competitors

$19.34 -0.01 (-0.05%)

As of 01:21 PM Eastern

Compare

DNLI vs. BEAM, RDY, ELAN, ARWR, and ABVX

Should you buy Denali Therapeutics stock or one of its competitors? MarketBeat compares Denali Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Denali Therapeutics include Beam Therapeutics (BEAM), Dr. Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Arrowhead Pharmaceuticals (ARWR), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry.

How does Denali Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, Beam Therapeutics had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 5 mentions for Beam Therapeutics and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.26 beat Beam Therapeutics' score of 0.96 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Beam Therapeutics presently has a consensus target price of $46.83, suggesting a potential upside of 60.94%. Denali Therapeutics has a consensus target price of $34.25, suggesting a potential upside of 77.19%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Denali Therapeutics is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Denali Therapeutics	N/A	-52.20%	-43.86%

Beam Therapeutics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

Beam Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	21.42	-$79.99M	-$0.68	N/A
Denali Therapeutics	$330.53M	9.28	-$512.54M	-$2.88	N/A

Summary

Beam Therapeutics and Denali Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to Dr. Reddy's Laboratories?

Denali Therapeutics (NASDAQ:DNLI) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

In the previous week, Dr. Reddy's Laboratories had 7 more articles in the media than Denali Therapeutics. MarketBeat recorded 9 mentions for Dr. Reddy's Laboratories and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.26 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dr. Reddy's Laboratories has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.28	-$512.54M	-$2.88	N/A
Dr. Reddy's Laboratories	$335.93B	0.03	$484.20M	$0.58	22.43

Denali Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Denali Therapeutics currently has a consensus target price of $34.25, indicating a potential upside of 77.19%. Dr. Reddy's Laboratories has a consensus target price of $16.90, indicating a potential upside of 29.90%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Denali Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Denali Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

Summary

Denali Therapeutics beats Dr. Reddy's Laboratories on 9 of the 17 factors compared between the two stocks.

How does Denali Therapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Elanco Animal Health has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

In the previous week, Elanco Animal Health had 13 more articles in the media than Denali Therapeutics. MarketBeat recorded 15 mentions for Elanco Animal Health and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.26 beat Elanco Animal Health's score of 1.18 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	9 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elanco Animal Health presently has a consensus price target of $28.20, indicating a potential upside of 16.82%. Denali Therapeutics has a consensus price target of $34.25, indicating a potential upside of 77.19%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Denali Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Elanco Animal Health has higher revenue and earnings than Denali Therapeutics. Elanco Animal Health is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.56	-$232M	-$0.50	N/A
Denali Therapeutics	$330.53M	9.28	-$512.54M	-$2.88	N/A

Denali Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Denali Therapeutics	N/A	-52.20%	-43.86%

Summary

Elanco Animal Health and Denali Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to Arrowhead Pharmaceuticals?

Denali Therapeutics (NASDAQ:DNLI) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

In the previous week, Arrowhead Pharmaceuticals had 6 more articles in the media than Denali Therapeutics. MarketBeat recorded 8 mentions for Arrowhead Pharmaceuticals and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.26 beat Arrowhead Pharmaceuticals' score of 1.05 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics currently has a consensus price target of $34.25, suggesting a potential upside of 77.19%. Arrowhead Pharmaceuticals has a consensus price target of $87.80, suggesting a potential upside of 20.37%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Denali Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Arrowhead Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Arrowhead Pharmaceuticals has higher revenue and earnings than Denali Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.28	-$512.54M	-$2.88	N/A
Arrowhead Pharmaceuticals	$622.01M	16.52	-$1.63M	-$2.15	N/A

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Denali Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

Denali Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Denali Therapeutics' return on equity of -52.20% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Summary

Denali Therapeutics beats Arrowhead Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to Abivax?

Denali Therapeutics (NASDAQ:DNLI) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Denali Therapeutics' return on equity of -52.20% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Abivax	N/A	-99.02%	-70.26%

Denali Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Abivax has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

Denali Therapeutics currently has a consensus target price of $34.25, suggesting a potential upside of 77.19%. Abivax has a consensus target price of $133.15, suggesting a potential upside of 60.43%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Denali Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Abivax	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Abivax has lower revenue, but higher earnings than Denali Therapeutics. Abivax is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.28	-$512.54M	-$2.88	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

In the previous week, Abivax had 22 more articles in the media than Denali Therapeutics. MarketBeat recorded 24 mentions for Abivax and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.26 beat Abivax's score of 0.18 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	3 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	4 Very Negative mention(s)	Neutral

Summary

Denali Therapeutics beats Abivax on 12 of the 14 factors compared between the two stocks.

Get Denali Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNLI vs. The Competition

Export

Metric	Denali Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.07B	$3.26B	$6.26B	$12.44B
Dividend Yield	N/A	2.33%	2.69%	5.30%
P/E Ratio	-6.71	17.75	22.35	24.23
Price / Sales	9.28	323.71	555.60	126.08
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	2.80	6.55	9.82	6.73
Net Income	-$512.54M	$24.20M	$3.56B	$336.97M
7 Day Performance	-4.35%	-3.25%	-1.16%	0.79%
1 Month Performance	5.63%	0.48%	3.85%	5.38%
1 Year Performance	38.77%	47.06%	27.33%	34.55%

Denali Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNLI Denali Therapeutics	3.7437 of 5 stars	$19.34 -0.1%	$34.25 +77.1%	+38.6%	$3.07B	$330.53M	N/A	430	Positive News
BEAM Beam Therapeutics	2.3268 of 5 stars	$28.64 flat	$46.83 +63.5%	+78.9%	$2.95B	$139.74M	N/A	510
RDY Dr. Reddy's Laboratories	2.8702 of 5 stars	$13.60 0.0%	$16.90 +24.3%	-11.6%	$11.35B	$3.58B	23.44	27,811	Analyst Revision
ELAN Elanco Animal Health	4.0025 of 5 stars	$21.77 +0.2%	$28.20 +29.5%	+76.0%	$10.85B	$4.72B	N/A	9,400	News Coverage Positive News
ARWR Arrowhead Pharmaceuticals	3.1452 of 5 stars	$74.95 flat	$87.80 +17.1%	+331.8%	$10.56B	$829.45M	N/A	400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DNLI) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Denali Therapeutics (DNLI) Competitors

DNLI vs. BEAM, RDY, ELAN, ARWR, and ABVX

How does Denali Therapeutics compare to Beam Therapeutics?

Summary

How does Denali Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Denali Therapeutics compare to Elanco Animal Health?

Summary

How does Denali Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Denali Therapeutics compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI vs. The Competition

Denali Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Denali Therapeutics (DNLI) Competitors

DNLI vs. BEAM, RDY, ELAN, ARWR, and ABVX

How does Denali Therapeutics compare to Beam Therapeutics?

Does the media refer more to BEAM or DNLI?

Do insiders & institutionals have more ownership in BEAM or DNLI?

Do analysts rate BEAM or DNLI?

Is BEAM or DNLI more profitable?

Which has more risk and volatility, BEAM or DNLI?

Which has preferable earnings and valuation, BEAM or DNLI?

Summary

How does Denali Therapeutics compare to Dr. Reddy's Laboratories?

Does the media refer more to DNLI or RDY?

Which has higher earnings and valuation, DNLI or RDY?

Which has more risk & volatility, DNLI or RDY?

Do institutionals & insiders believe in DNLI or RDY?

Do analysts rate DNLI or RDY?

Is DNLI or RDY more profitable?

Summary

How does Denali Therapeutics compare to Elanco Animal Health?

Which has more risk & volatility, ELAN or DNLI?

Does the media refer more to ELAN or DNLI?

Do analysts recommend ELAN or DNLI?

Do insiders & institutionals believe in ELAN or DNLI?

Which has better earnings and valuation, ELAN or DNLI?

Is ELAN or DNLI more profitable?

Summary

How does Denali Therapeutics compare to Arrowhead Pharmaceuticals?

Does the media prefer DNLI or ARWR?

Do analysts rate DNLI or ARWR?

Which has preferable earnings & valuation, DNLI or ARWR?

Do insiders & institutionals hold more shares of DNLI or ARWR?

Which has more risk and volatility, DNLI or ARWR?

Is DNLI or ARWR more profitable?

Summary

How does Denali Therapeutics compare to Abivax?

Is DNLI or ABVX more profitable?

Which has more volatility & risk, DNLI or ABVX?

Do analysts recommend DNLI or ABVX?

Do insiders & institutionals hold more shares of DNLI or ABVX?

Which has stronger earnings & valuation, DNLI or ABVX?

Does the media prefer DNLI or ABVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI vs. The Competition

Denali Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools